journal
Journals Clinical Lymphoma, Myeloma & L...

Clinical Lymphoma, Myeloma & Leukemia

https://read.qxmd.com/read/38341324/soho-state-of-the-art-updates-and-next-questions-diagnosis-outcomes-and-management-of-prefibrotic-myelofibrosis
#21
REVIEW
Pankit Vachhani, Sanam Loghavi, Prithviraj Bose
Prefibrotic primary myelofibrosis (prefibrotic PMF) is a myeloproliferative neoplasm with distinct characteristics comprising histopathological and clinico-biological parameters. It is classified as a subtype of primary myelofibrosis. In clinical practice, it is essential to correctly distinguish prefibrotic PMF from essential thrombocythemia especially but also overt PMF besides other myeloid neoplasms. Risk stratification and survival outcomes for prefibrotic PMF are worse than that of ET but better than that of overt PMF...
January 21, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38331676/soho-state-of-the-art-updates-and-next-questions-will-car-t-replace-asct-in-ndmm
#22
REVIEW
Eric Jurgens, Saad Z Usmani
The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last 2 decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive...
January 19, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38378362/venetoclax-and-cobimetinib-in-relapsed-refractory-aml-a-phase-1b-trial
#23
JOURNAL ARTICLE
Marina Y Konopleva, Monique Dail, Naval G Daver, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Agostino Tafuri, Joseph M Brandwein, Arnaud Pigneux, Bayard L Powell, Pierre Fenaux, Rebecca L Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Diana Dunshee, Habib Hamidi, Marion G Ott, Wan-Jen Hong, Michael Andreeff
BACKGROUND: Therapies for relapsed/refractory acute myeloid leukemia remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. PATIENTS AND METHODS: This phase 1b trial evaluated venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor, plus cobimetinib, a MEK1/2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia, ineligible for cytotoxic chemotherapy. Two-dimensional dose-escalation was performed for venetoclax dosed daily, and for cobimetinib dosed on days 1-21 of each 28-day cycle...
January 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38336492/serologic-response-to-vaccine-for-covid-19-in-patients-with-hematologic-malignancy-a-prospective-cohort-study
#24
JOURNAL ARTICLE
Alexandra Hillyer, Anthony Quint, Artin Ghassemian, Nicolette Joh-Carnella, Michael J Knauer, Danny Dawd, Alejandro Lazo-Langner, Joy Mangel, Selay Lam, Husam Abdoh, Anargyros Xenocostas, Uday Deotare, Lalit Saini, Cheryl Foster, Martha Louzada, Jenny Ho, Ian Chin-Yee, Chai W Phua
BACKGROUND: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies. PATIENTS AND METHODS: We conducted a prospective cohort study, collecting samples from March 2021 to July 2022, from patients seen at a cancer treatment center in London, Ontario, Canada, who met the following eligibility criteria: age ≥18 years, diagnosed with a hematological malignancy, recipient of a COVID-19 vaccine during the study period, and able to provide informed consent...
January 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38342727/geographic-and-racial-disparities-in-chimeric-antigen-receptor-t-cells-and-bispecific-antibodies-trials-access-for-diffuse-large-b-cell-lymphoma
#25
JOURNAL ARTICLE
Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, Ahmad Basharat, Mohammad Ammad-Ud-Din, Robin Park, Iqra Anwar, Muhammad Salman Faisal, Michael Jaglal
BACKGROUND: We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. MATERIALS AND METHODS: ClinicalTrials.gov was searched, and 75 trials with at least 1 open site in the US were included. 2020 US Census Bureau data was used to obtain data on race and ethnicity. SPSS version 26 was used for analysis. RESULTS: There were 62 CAR-T and 13 bispecific antibodies trials with 6221 enrolled or expected to enroll patients...
January 17, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38342726/prognostic-impact-of-bone-marrow-fibrosis-and-effects-of-tyrosine-kinase-inhibitors-on-bone-marrow-fibrosis-in-chronic-myeloid-leukemia
#26
JOURNAL ARTICLE
Mehmet Sezgin Pepeler, Mesut Tıglıoglu, Simten Dagdas, Esra Ozhamamcıoglu, Unsal Han, Aynur Albayrak, Mürüvvet Seda Aydın, Gülten Korkmaz, Merve Pamukcuoğlu, Funda Ceran, Murat Albayrak, Gülsüm Ozet
BACKGROUND: Myelofibrosis is reported in around 40% of newly diagnosed chronic myeloid leukemia (CML) patients and have an important role in the pathobiology and prognosis of CML. This retrospective study aimed to evaluate the effects of bone marrow (BM) fibrosis on disease prognosis and the effects of specific tyrosine-kinase inhibitors (TKIs) on BM fibrosis in CML patients. METHODS: The study included 96 patients (>18 years) diagnosed with chronic phase (CP) CML...
January 17, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38278737/a-review-of-the-therapeutic-role-of-bosutinib-in-chronic-myeloid-leukemia
#27
REVIEW
Hagop M Kantarjian, Elias J Jabbour, Jeffrey H Lipton, Fausto Castagnetti, Tim H Brümmendorf
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerated phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML...
January 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38267353/chimeric-antigen-receptor-t-cell-therapy-for-large-b-cell-lymphoma-patients-with-central-nervous-system-involvement-a-systematic-review-and-meta-analysis
#28
REVIEW
Ghada Elgohary, Yang Yang, Mia Gergis, Dongni Yi, Usama Gergis
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed and Cochrane Library to identify all published literature associated with United States Food and Drug Administration approved CAR T-cell therapies for LBCL...
January 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38267354/soho-state-of-the-art-updates-and-next-questions-ctls-for-infections-following-stem-cell-transplantation
#29
REVIEW
Ariel Rischall, Amanda Olson
Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity...
January 9, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38195323/soho-state-of-the-art-updates-and-next-questions-next-questions-acute-lymphoblastic-leukemia
#30
REVIEW
Jayastu Senapati, Hagop Kantarjian, Fadi G Haddad, Nicholas J Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%...
January 8, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38220589/an-open-label-phase-i-study-of-metformin-and-nelfinavir-in-combination-with-bortezomib-in-patients-with-relapsed-and-refractory-multiple-myeloma
#31
JOURNAL ARTICLE
Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel P Burbano, Patrick J O'Brien, Francis K Buadi, Suzanne Hayman, Shaji K Kumar, Wilson I Gonsalves
BACKGROUND: In preclinical models, combining a GLUT4 inhibitor with an oxidative phosphorylation inhibitor shows synergistic therapeutic potential against multiple myeloma (MM). Thus, this study evaluated the safety and tolerability of repurposing metformin, a complex I inhibitor, and nelfinavir, a GLUT4 inhibitor, in combination with bortezomib for the treatment of relapsed/refractory MM that had progressed on all standard of care therapies. MATERIALS AND METHODS: This trial utilized a 3 + 3 dose escalation design with 3 dose levels planned for up to a maximum of 6 (21-day) cycles...
January 6, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38245472/racial-disparities-in-mycosis-fungoides-s%C3%A3-zary-syndrome-a-single-center-observational-study-of-292-patients
#32
JOURNAL ARTICLE
Ashley R Gandham, Shamir Geller, Stephen W Dusza, Thomas S Kupper, Patricia L Myskowski
BACKGROUND: Clinical presentation of Mycosis fungoides/Sézary syndrome (MF/SS) in Black and African American (AA) patients can be heterogeneous with poor survival reported in AA/black patients. In this study, we aim to characterize differences between AA/black and white patients with MF/SS. PATIENTS AND METHODS: A retrospective single-center hospital-based case-control study including 292 MF/SS patients (146 AA/black matched with 146 white patients). We analyzed demographic, clinical and survival differences...
January 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38212207/dose-dense-mini-hyper-cvd-inotuzumab-ozogamicin-and-blinatumomab-achieves-rapid-mrd-negativity-in-philadelphia-chromosome-negative-b-cell-acute-lymphoblastic-leukemia
#33
JOURNAL ARTICLE
Nicholas J Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G Haddad, Lewis F Nasr, Kayleigh R Marx, Caitlin Rausch, J Michael Savoy, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian
BACKGROUND: The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, "dose-dense" administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes. PATIENTS AND METHODS: We performed a retrospective analysis of the safety and efficacy of a dose-dense regimen of mini-hyper-CVD (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with mini-methotrexate and cytarabine), INO, and blinatumomab in patients with B-cell ALL...
December 30, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38151388/improvements-in-patient-reported-outcomes-in-relapsed-or-refractory-large-b-cell-lymphoma-patients-treated-with-epcoritamab
#34
JOURNAL ARTICLE
Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Nurgul Kilavuz, Catherine Thieblemont
BACKGROUND: Patient-reported outcomes were evaluated in EPCORE NHL-1 in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with epcoritamab monotherapy (NCT03625037). MATERIALS AND METHODS: Adults with R/R CD20+ LBCL and ≥2 prior systemic antilymphoma therapies, including anti-CD20, completed the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and EQ-5D-3L. A subgroup of patients provided additional feedback in one-on-one qualitative interviews...
March 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38072743/pomalidomide-bortezomib-and-dexamethasone-in-lenalidomide-pretreated-multiple-myeloma-a-subanalysis-of-optimismm-by-frailty-and-bortezomib-dose-adjustment
#35
JOURNAL ARTICLE
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, Meral Beksac, Thierry Facon, Sujith Dhanasiri, Shien Guo, Yutian Mu, Kevin Hong, Christian Gentili, Monica Galli, Munci Yagci, Alessandra Larocca, Paul Richardson, Katja Weisel
INTRODUCTION: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. This subanalysis of OPTIMISMM assessed outcome by frailty and/or bortezomib dose adjustment. METHODS: Patient frailty (nonfrail vs. frail) was classified using age, Charlson Comorbidity Index, and Eastern Cooperative Oncology Group performance status...
March 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38000981/survival-outcomes-of-limited-stage-diffuse-large-b-cell-lymphoma-treated-with-radiation-therapy
#36
JOURNAL ARTICLE
Daniel A Ermann, Victoria A Vardell, Harsh Shah, Lindsey Fitzgerald, Randa Tao, David K Gaffney, Deborah M Stephens, Boyu Hu
BACKGROUND: Patients with favorable risk limited-stage (LS) diffuse large b-cell lymphoma (DLBCL) have shown excellent outcomes without radiotherapy (RT). However, the role of RT for the remainder of LS-DLBCL patients is less well defined. We aimed to investigate whether the addition of RT provided an overall survival (OS) benefit in a real-world cohort of LS-DLBCL patients based on primary site at presentation. MATERIALS AND METHODS: Retrospective data from 39,745 patients with stage I and II DLBCL treated with front-line combination chemotherapy alone or followed by RT were identified using the National Cancer Database from 2004 to 2015...
February 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37981564/indirect-treatment-comparisons-of-mosunetuzumab-with-third-and-later-line-treatments-for-relapsed-refractory-follicular-lymphoma
#37
JOURNAL ARTICLE
Francesc Bosch, John Kuruvilla, Theodoros P Vassilakopoulos, Danilo Di Maio, Michael C Wei, Marie-Helene Blanchet Zumofen, Loretta J Nastoupil
BACKGROUND: No established standard of care exists for relapsed/refractory (RR) follicular lymphoma (FL) after ≥2 prior therapies. We conducted indirect treatment comparisons (ITCs) to compare the efficacy and tolerability of mosunetuzumab with those of available treatments used in this setting. METHODS: A systematic literature review (SLR) and subsequent feasibility assessments were conducted to identify the most suitable comparator studies in terms of design, available endpoints and populations...
February 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37973459/outcome-of-multiple-myeloma-patients-with-hepatitis-b-surface-antigen-korean-multiple-myeloma-working-party-2103-study
#38
MULTICENTER STUDY
Jun Ho Yi, Jung Lim Lee, Yoo Jin Lee, Hye Jin Kang, Young Hoon Park, Young Jin Yuh, Sung-Nam Lim, Hyo Jung Kim, Sung-Hoon Jung, Je-Jung Lee, Hee Jeong Cho, Joon Ho Moon, Ho-Young Yhim, Kihyun Kim
BACKGROUND: Hepatitis B virus reactivation (HBVr) is a well-known complication of systemic chemotherapy for particularly hematologic malignancies in HBV carriers. We performed a multicenter retrospective study to investigate the incidence and risk factors of HBVr in patients with hepatitis B surface antigen (HBsAg)-positive multiple myeloma (MM). METHODS: We included 123 patients with HBsAg-positive MM who had received systemic therapy. The primary objective of the study was to evaluate the incidence of HBVr in patients with HBsAg-positive MM...
February 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37973458/soho-state-of-the-art-updates-and-next-questions-treatment-for-newly-diagnosed-peripheral-t-cell-lymphomas
#39
REVIEW
Jackson S Burton, Nicole C Foley, Neha Mehta-Shah
Although a rare subset of non-Hodgkin lymphomas, peripheral T-cell lymphomas (PTCL) account for a disproportionate proportion of patient mortality. Conventional therapies are derived from experience treating aggressive B-cell lymphomas and center around CHOP-based chemotherapy. However, due to the unique biology and diverse subtypes of PTCL, most patients fail to durably respond to this approach and 5-year survival is only 20% to 30%. There have been multiple attempts to improve outcomes for patients with PTCL...
February 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/37867093/full-dose-azacitidine-in-5-days-versus-7-days-with-a-weekend-break-in-myelodysplastic-syndromes-a-retrospective-cohort-study
#40
JOURNAL ARTICLE
Guilherme Sapinho, Lídia Alves-Ribeiro, Joana Infante, Catarina Jacinto-Correia, Sahir Kalim, João F Lacerda
INTRODUCTION: Apart from transplantation, only azacitidine demonstrated a survival benefit in a phase III study in higher-risk myelodysplastic syndromes (MDS). The approved regimen is 75 mg/m2 /day for 7 consecutive days, imposing a logistic challenge for outpatient weekend administration. Schedules with 5 days and 7 days with a weekend break (5 + 2) have been used for convenience despite the lack of strong scientific support. Most studies of alternative schedules were performed in lower-risk MDS and with dose reduction in the 5-day schedules...
February 2024: Clinical Lymphoma, Myeloma & Leukemia
journal
journal
42898
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.